They possessed an increased phagocytic capacity enabling a superior antibody-dependent phagocytosis of multiple myeloma (MM) and lymphoma cells that were treated with anti-CD38 or anti-CD20 mAbs, respectively. This evidence concerns the gene CD38 and lymphoma.